Are Specific Treatment-side effects a Good Sign?

Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has become a standard cancer treatment.

However, 20-40% of patients suffer from cutaneous adverse events while receiving it.

A new study challenges the perception that these effects should only be treated as a negative outcome.

The researchers compared medical information of more than 14,000 advanced cancer patients who received ICIs, half who experienced skin-related side effects and half who did not.

They have found that those who experienced at least one skin-related adverse event had a 22% decrease in mortality.

They concluded that these side effects might be linked to better response to ICIs and improved survival.

More studies are required to understand the mechanism underlying these findings.

developments

For more info:

https://ascopost.com/news/january-2022/is-the-development-of-cutaneous-immune-related-adverse-events-correlated-with-response-to-immunotherapy

At Belong, we will continue to update you with new medical and research

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment.

Belong.Life is a leading global tech provider of high-engagement patient communities and care platforms, supporting millions of patients worldwide.

Among Belong.Life’s brands are the world’s largest social and professional networks for cancer patients (Belong – Beating Cancer Together) and multiple sclerosis patients (BelongMS), as well as i-Belong, BelongIBD, BelongPSOCoronApp (select countries), and more.

Belong.Life’s mission is to improve quality of life and quality of care worldwide through technology, engagement, data, and AI.

Skip to content